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Abstract
Membrane transporter proteins play critical physiological roles in the cell and constitute 5–10% of prokaryotic and eukaryotic genomes.
High-resolution structural information is essential for understanding the functional mechanism of these proteins. A prerequisite for structural
study is to overexpress such proteins in large quantities. In the last few years, over 20 bacterial membrane transporters were overexpressed at
a level of 1 mg/liter of culture or higher, most often in Escherichia coli. In this review we analyzed those factors that affect the quantity and
quality of the protein produced, and summarized recent progress in overexpression of membrane transporters from bacterial inner membrane.
Rapid progress in genome sequencing provides opportunities for expressing several homologues and orthologues of the target protein
simultaneously, while the availability of various expression vectors allows flexible experimental design. Careful optimization of cell culture
conditions can drastically improve the expression level and homogeneity of the target protein. New sample preparation techniques for mass
spectrometry of membrane proteins have enabled one to identity the rigid protein core, which can be subsequently overexpressed. Size-
exclusion chromatography on HPLC has proven to be an efficient method in screening detergent, pH an other conditions required for
maintaining the stability and monodispersity of the protein. Such high-quality preparations of membrane transporter proteins will probably
lead to successful crystallization and structure determination of these proteins in the next few years.
D 2003 Elsevier Science B.V. All rights reserved.
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1. Introduction
To survive and function properly, cells exchange sub-
stances such as nutrients, ions, and metabolites with their
environment. These tasks are performed by transporter
proteins that are embedded in the cell membrane. Membrane
transporters account for 5–10% of proteins in bacterial
genomes [1,2] and 3% of the human genome [3,4] (Table
1). A majority of these transport proteins use either ion or
solute gradients as the driving force to translocate substrates
across the membrane, and they are called secondary trans-
porters. Based on phylogenetic analysis, secondary trans-
porter proteins have been classified into over 100 families
and superfamilies [1,2,5]. The larger family, the major
facilitator superfamily (MFS), currently has more than
1000 identified members, and they account for about 25%
of all transporter proteins [6].
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In human cells, membrane transporters play vital roles in
physiological processes and their dysfunction is implicated
in a variety of diseases. For example, type II diabetes is due
to the impairment of the glucose uptake process in muscle
and fat cells, which is mediated by the glucose transporter
Glut4 [7–9]. Glycogen storage disease type I is caused by a
deficiency in the glucose-6-phosphate transporter (G6PT)
[10]. In amyotrophic lateral sclerosis, Huntington’s disease
and Alzheimer’s disease, the number of glutamate trans-
porters per unit mass of brain tissue is decreased [11,12].
Again in the brain, cocaine exerts its addictive effects by
directly blocking the dopamine transporter [13]. Equally
important for human health is bacterial antibiotic resistance,
which is caused largely by transporter proteins acting as
drug efflux pumps [14,15].
Mutagenesis and functional studies on membrane trans-
porters have yielded detailed information on the individual
amino acid residues responsible for substrate binding and
translocation [16–20]. However, because no high-resolution
structure has been determined for any secondary transporter
protein from either eukaryotic sources or bacterial inner
membrane, substrate specificity and diversity as well as the
molecular mechanisms underlying membrane transport for
these proteins remain poorly understood.
An overexpression system for membrane transporters is a
prerequisite for structural studies. This is because tens, and
sometimes hundreds, of milligrams of highly purified sam-
ples are needed for those experiments, and few transporter
proteins are abundant in natural sources. In addition, protein
produced using an overexpression system is more homoge-
neous than that from natural sources, and therefore can yield
crystals more readily. The target protein can also be manip-
ulated at the gene level in an expression system, allowing
crystallization attempts of different protein constructs. At
present, almost no such overexpression system exists for
any mammalian transporter [21], and for that matter, for
membrane proteins from mammalian sources. However, a
bacterial homologue can be used as a prototype to obtain the
essential information on the structure and mechanism for its
mammalian homologue. Indeed, over two-dozen secondary
transporter proteins have been overexpressed and purified in
milligram quantities (Table 2). Their substrates range from
ions, sugars, sugar–phosphates, amino acids, to peptides.
Successful expression and purification, together with tech-
nical advances in membrane protein crystallization [22,23],
will probably lead to structure determination of a number of
secondary transporters at high resolution in the near future.
In the current review, we discuss practical aspects that are
important for producing membrane transporters for struc-
tural studies. Readers can consult other reviews on princi-
ples of protein expression [24,25] and protocols for over-
expressing membrane proteins [26–29]. The expression
yield and protein quality are critical to the crystallization
experiment and both are affected by multiple factors at the
stages of transcription, translation, and membrane insertion.
Thus, we have grouped the factors into those important for
the expression level, and those critical for the protein
quality. Understandably, such a classification scheme is
somewhat artificial, because, for example, cell culture con-
ditions affect both the quantity and quality of the expressed
protein. Still, this scheme is particularly helpful to readers
with practical questions like: ‘How do I increase the yield of
my membrane protein expression system?’, ‘How can I
improve the quality of my protein by optimizing cell culture
conditions?’ or, ‘How can I stabilize my transporter protein
after purification?’. We focus on secondary transporters
from bacterial sources and primarily discuss the Escherichia
coli system, because almost all studies on overexpression of
secondary membrane transporters have been carried out in
this system [30–32]. In addition, only those studies where a
purification yield of 0.5 mg of protein per liter of bacterial
culture or higher was obtained will be considered useful for
structural work. Finally, we discuss future directions for
overexpression of bacterial and eukaryotic membrane trans-
porters in E. coli.
2. Factors important for expression level
E. coli is the system of choice for producing bacterial
membrane transporters for structural studies. Most impor-
tantly, the likelihood of overexpressing bacterial membrane
transporters in E. coli is relatively high. In addition, its low-
cost, high growth rate, well-characterized genetics, and the
availability of large number of cloning vectors make E. coli
particularly attractive for large-scale protein expression
[25,33].
2.1. Choice of protein target
Sequence data from genomics projects, the availability of
genomic DNA and development in polymerase chain reac-
tion (PCR) cloning techniques have made it possible to
clone almost any transporter protein. As a result, multiple
members of the protein family of interest can be selected for
overexpression and crystallization simultaneously using a
strategy commonly referred to as searching of crystalliza-
tion space by cloning [23,34,35].
Table 1
Number of transporters identified in genomes to date
Genes Transporters Transporter
families
MFSa APCb
Escherichia coli [90] 4282 297 59 66 22
Bacillus subtilis [91] 4100 262 51 65 18
Thermoplasma
acidophilum [92]
1509 142 n.a.c n.a.c >12
Saccharomyces
cerevisiae [93]
6141 258 42 78 24
Human [3,4] 26,383 1006 n.a.c n.a.c n.a.c
a Major facilitator superfamily.
b Amino-proline-choline transporter family.
c Information not yet available.
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Table 2
Overexpressed bacterial secondary membrane transporters of various families
Protein and
organisma
Expression host
and vector
Cell culture Protein
purification
Expression
level and
purification
yield
Activity assay Comments
MFS (2.A.1)b
AraE
Escherichia coli
E. coli AD5827
(K12 derivative),
pAD284
Growth to OD600 = 0.45
at 33 jC in minimal
medium, rapid shift to
42 jC, harvest 3 h
post induction
No purification 7% of total
membrane
protein
Transport
assay in
cells
[80]
AraE
Klebsiella oxytoca
E. coli MM23,
pUC18
Growth in the presence
of 10 mM L-arabinose
as inducer
No purification n.a.c Transport
assay in
cells
[94]
Bmr
Bacillus
subtilis
E. coli NO2947,
pTTQ18,
tac promoter
n.a.c Nickel–
nitrilotriacetic
acid (Ni2 +–NTA)
affinity column
20% of inner
membrane
protein
n.a.c No tight regulation
of promoter,
expression without
inducer [37]
FucP
Escherichia coli
E. coli AR120
and BL21 (DE3)
pLys, pSPT19
Growth to OD600 = 0.4
at 37 jC in 2xTY,
induction with 40 Ag/ml
nalidixic acid,
harvest 1–6 h post
induction
n.a.c 20% of total
inner membrane
protein
Transport
assay in
cells
Poor expression
under control of T7
promoter,
only E OLPL
successful [95]
GalP
Escherichia coli
E. coli JM1100,
pBR322
Growth at 37 jC,
no induction
Sucrose gradient,
Ni2 +–NTA
affinity and
ion exchange
columns
35–55% of total
inner membrane
protein
Reconstitution
and transport
assay
Expression
under control
of galP [28,36,
96,97]
GlpT
Escherichia coli
E. coli LMG194,
pBAD
Growth 3 h at 37 jC,
change to 25 jC 0.5 h
before induction
(0.1% arabinose,
OD600 = 1), harvest
1.5 h post induction
at OD600 = 1.5–1.8
Ni2 +–NTA
affinity and
size-exclusion
columns
1.5–1.8 mg
purified per
liter culture
Fluorescence
quenching,
reconstitution
and transport
assay
Enhanced
stability by C-
terminal
truncation,
identified
by limited
proteolysis [42]
LacY (I)
Escherichia coli
In vitro translation
using T7
polymerase,
pT75
– Sucrose gradient n.d.d Reconstitution Membrane-free
translation
system,
co-expression
with GroEL [98]
LacY (II)
Escherichia coli
E. coli XL blue,
cassette version of
lacY (Acc X56095),
lac promoter
Growth to OD600 = 0.8
at 37 jC, induction with
0.3 mM isopropyl-h-D-
thiogalactopyranoside
(IPTG), harvest
at OD=2
Ni2 +–NTA
affinity column
1.2 mg per liter
culture
Transport
assay in cells
Expressed as
cytochrome b562
fusion protein
[63,81]
LacY (III)
Escherichia coli
E. coli T184,
pGM21 (derived
from pBR322)
Growth to OD420 = 0.2
at 37 jC, induction with
0.1 mM IPTG, harvest
2 h post induction
at OD420 = 1.2–1.6
avidin affinity
column
f 10% of total
membrane protein,
2 mg purified
from 20 g cells
Reconstitution
and transport
assay
Expressed as
biotin acceptor
domain fusion
protein [86,99]
NorA
Staphylococcus
aureus
E. coli DH10B,
pTrcHis2C
Growth to OD600 = 0.8
at 37 jC. Induction with
0.5 m M IPTG, harvest
4 h post induction
Ni2 +–NTA
affinity column
5–10% of total
membrane protein,
0.5–1 mg purified
per liter culture
Reconstitution
and transport
assay
[100]
OxlT
Oxalobacter
formigenes
E. coli XL3
(E. coli XL1 blue
harboring pMS421),
pBluescript II SK
Growth to OD600 =
0.2–0.3 at 37 jC,
induction with 1 mM
IPTG, harvest 4 h
post induction
Ni2 +–NTA
affinity column
5% of total
membrane protein,
0.5–1 mg purified
per liter culture
Reconstitution
and transport
assay
His10-tag,
higher yield with
C-terminal tag
[71,101]
(continued on next page)
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Table 2 (continued)
Protein and
organisma
Expression host
and vector
Cell culture Protein
purification
Expression
level and
purification
yield
Activity assay Comments
MFS (2.A.1)b
ProP
Escherichia coli
E. coli WG389
(K12 derivative),
pBR322 (modified
galP promoter)
Growth at 37 jC
for 18 h to final
OD600 = 6 in
minimal medium
Ni2 +–NTA
affinity column
30% of total
membrane
protein, 0.5 mg
from 50 mg
membrane protein
Reconstitution
and transport
assay
Significant
reduced expression
in rich medium
[36,102]
TetA
Escherichia coli
E. coli DH5a
pET21b,
co-transformed
with pACT7
Growth to OD530 = 0.8
at 37 jC, induction
with 0.1 mM IPTG,
harvest 1.5–2 h
post induction
Ni2 +–NTA
affinity column
10–15% of total
membrane protein,
1–1.5 mg purified
from 1 l culture
Fluorescence
binding
[44]
TetL
Bacillus subtilis
E. coli BL21
(DE3) pLysS,
pET15b
Growth 2.5 h
at 30 jC, change
to 20 jC 0.4 h
before induction
with 1 mM IPTG at
OD600 = 1, harvest
1.8 h post induction
at OD600 = 1.4–1.7
Co2 +-Talon
affinity and
size exclusion
columns
1 mg purified
after Co2 +-Talon
and 0.2–0.3 mg
after size exclusion
column per liter
culture
Reconstitution
and transport
assay
[45]
UhpT
Escherichia coli
E. coli JM109,
p261 (derived
from pBR322),
co-transformed
with pMS421
Growth 3.5 h
at 37 jC, change to
34 jC, induction with
1 mM IPTG,
harvest 2–3 h post
induction
Ni2 +–NTA
affinity
column
25 Ag purified
from 4 mg
membrane protein
Reconstitution
and transport
assay
Purification in
presence of
50 mM G6P, N-
terminal His10-tag
[103]
XylE
Escherichia coli
E. coli NO2947,
pTTQ18
Growth at 37 jC,
induction with
1 mM IPTG
n.a.c 20% of inner
membrane protein
n.a.c Highest
expression with tac
promoter, with PL
expression 5–8%
[28,36]
GPH (2.A.2)
GusB
Escherichia coli
E. coli NO2947,
pTTQ18
Growth at 37 jC,
induction with
0.6 mM IPTG
n.a.c 20% of inner
membrane protein
n.a.c [28,36]
LacS (I)
Streptococcus
thermophilus
E. coli NO2947,
pSKE8
Growth in M9
minimal medium
at 37 jC
No purification 8% of total
membrane protein
n.d.d Expression lower
and solubilization
less efficient than
in S. thermophilus
[30]
LacS (II)
Streptococcus
thermophilus
S. thermophilus
ST11 and ST11
(DlacS), pGK13
Growth in Elliker
Broth to OD660 =
0.8–1 at 42 jC,
semi-anaerobic
conditions, induction
with lactose
Ni2 +–NTA
affinity and
ion-exchange
columns
25–30% of total
membrane protein,
4–5 mg purified
from 1 l culture
Reconstitution
and transport
assay
[30]
MelB
Escherichia coli
E. coli DW2-R,
pKK223
Growth to OD600 = 2
at 30 jC in M9
minimal medium
Ni2 +–NTA
affinity and
ion-exchange
columns
15% of total
membrane protein,
20–30 mg
purified from 10 g
cells
Transport
assay and
fluorescence
quenching
of reconstituted
proteoliposomes
N-terminally
truncated form
expressed
[104,105]
XylP
Lactobacillus
pentosus
L. lactis NZ9000,
pNZ8048
Growth to OD600 = 3
at 30 jC, induction
with 4 ng/ml nisin,
harvest 1 h
post induction
Ni2 +–NTA
affinity column
10% of total
membrane
protein
Reconstitution
and transport
assay
Fermentor was
used for cell
culture [32]
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Table 2 (continued)
Protein and
organisma
Expression host
and vector
Cell culture Protein
purification
Expression
level and
purification
yield
Activity assay Comments
APC (2.A.3)
GabP
Escherichia coli
E. coli LMG194,
pBAD
Growth to OD600 =
0.5–0.6 at 37 jC
for 2 h, induction with
0.2% arabinose,
change to 25 jC,
harvest 2 h post
induction at
OD600 = 1.0–1.1
Co2 +-Talon
affinity and
size-exclusion
columns
0.3–0.5 mg
purified per
liter culture
Fluorescence
quenching
upon substrate
binding
Identification of a
rigid protein core
using limited
proteolysis [41]
CSC (2.A.17)
DtpT
Lactococcus lactis
L. lactis
MG1363 and
AG300, dtpT
Growth in M17 broth
at 28 jC, no induction,
harvest in late
exponential phase
Ni2 +–NTA
affinity column
10% of total
membrane
protein, 2 mg
purified from
100 mg
membrane protein
Transport
assay in
cells and in
reconstituted
proteoliposomes
Overexpression of
the protein in
E. coli was lethal
[31]
SSS (2.A.21)
PutP
Escherichia coli
E. coli
WG170,
pT7-5
Growth to mid log
phase at 37 jC,
induction with
0.3 mM IPTG,
harvest 3 h post
induction
Ni2 +–NTA
affinity and
ion-exchange
columns
6 mg purified
from 90 mg of
total membrane
proteins
Reconstitution
and transport
assay
[106]
DAACS (2.A.23)
GltT
Bacillus
stearothermophilus
E. coli
DH5, pBlueScript
II KS
Growth to OD660 = 0.7
at 37 jC, harvest
without induction
Ni2 +–NTA
affinity column
0.7% of total
membrane protein,
3 mg purified
from 400 mg
membrane protein
Reconstitution
and transport
assay
No IPTG induction,
‘‘leaky’’ expression
[107]
CCS (2.A.24)
CitS
Klebsiella
pneumoniae
E. coli C43(DE3),
pET16b
Growth in terrific
broth to OD600 = 0.6
at 30 jC, induction
with 0.7 mM IPTG,
change to 25 jC,
harvest after 18–22 h
at OD600 = 10
Ni2 +–NTA
affinity column
6.5 mg purified
per liter culture
Reconstitution
and transport
assay
N-terminal
His10-tag, lower
yield in LB or with
biotinylated protein
[43]
AGCS (2.A.25)
AlcP Thermophilic
bacillus PS3
E. coli TB1,
pMAL-c2
Growth in NZCY
medium to late log
phase at 37 jC,
induction with 1 mM
IPTG, harvest 3 h
post induction
Amylose
affinity column
20% of total
membrane protein,
5 mg fusion
protein from
50 mg membrane
protein
Reconstitution
and transport
assay
Expressed as
maltose binding
protein fusion
protein [108]
NhaA (2.A.33)
NhaA
Escherichia coli
E. coli TA16
(K12 derivative),
pEP3T
Growth in minimal
medium to OD600 = 0.5
at 30 jC, induction
with 0.5 mM IPTG,
harvest 2 h post
induction
Hydroxylapatite
and ion-exchange
columns
438 Ag from
10 mg cells
Reconstitution
and transport
assay
[83]
(continued on next page)
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Among the members of the chosen protein family, trans-
porters that have been biochemically and functionally char-
acterized are worth considering, because such information
may help crystallization experiments. Members of the trans-
porter family with various loop lengths can be selected for
they may provide different crystal contacts. However, it is
not yet possible to predict the expression levels of a
particular protein from its sequence. It is thought that
proteins with multiple transmembrane a-helices tend to give
lower expression than those with fewer transmembrane
domains [25]. Recent studies, however, suggest that this
may not be the case. Indeed, the Mg2 + transporter (CorA)
and the mechanosensitive channel (MscL) from E. coli, both
predicted to have two to three transmembrane a-helices,
were expressed to a level of 10–15 mg protein per liter of E.
coli culture, from which 5–10 mg protein was purified
(Chen, Auer and Wang, unpublished results). For compar-
ison, expression of several transporter proteins with as many
as 12 predicted transmembrane a-helices produced levels of
20–50% of total membrane protein [28,36,37], although
often only 1–2 mg protein was purified per liter of cell
culture (Table 2). Therefore, high number of transmembrane
helices does not seem to be a limiting factor for protein
expression.
2.2. Expression vector
The vector is one of the most important factors for
overexpression of membrane transporter proteins. Whether
a protein target expresses in E. coli or not largely depends
on the vector. Ideally, the vector should have a tightly
regulated, moderately strong promoter, and should have a
wide range of usable inducer concentrations. Tight regula-
tion prevents leaky expression, which can lead to in vivo
proteolysis, or even cell death when expressing toxic
membrane proteins like certain amino acid transporters.
Very strong promoters tend to result in inclusion body
formation [38,39]. On the other hand, a wide range of
applicable inducer concentrations allows better control of
expression. Finally, the inducer should not be prohibitively
expensive, making scaling-up impossible. A number of
expression vectors meet the above criteria and have been
successfully used for overexpressing membrane transporter
proteins (Table 2).
The pBAD vectors from Invitrogen, containing the
arabinose araBAD operon, are particularly suitable for over-
expression of membrane proteins [40]. The promoter is
repressed 1200-fold, which allows tight regulation of
expression. It is moderately strong, and can be induced by
L-arabinose at concentrations between 0.00002% and 0.2%.
This expression system has been used to overexpress a
number of membrane proteins to a yield of 1 mg purified
protein per liter of culture or higher. These include the
mechanosensitive channel MscL, the GABA transporter
GabP [41], the G3P transporter GlpT [42], and the magne-
sium transporter CorA (Chen and Wang, unpublished
results). These proteins belong to four different protein
families (Table 2), demonstrating the general applicability
of the pBAD system.
Similarly, overexpression of several membrane trans-
porters has been achieved with the pET vector series [43–
45]. The gene expression in this system is under the control
of the T7 promoter, which is not recognized by E. coli RNA
polymerase. As a result, almost no expression occurs until
T7 RNA polymerase is provided with the vector [46]. The
entire vector series includes 36 pET vectors that are tailored
for different expression levels and have a variety of tags for
protein purification and detection. However, because the T7
Table 2 (continued)
Protein and
organisma
Expression host
and vector
Cell culture Protein
purification
Expression
level and
purification
yield
Activity assay Comments
NhaB (2.A.34)
NhaB
Escherichia coli
E. coli TA15
(K12 derivative),
pT7-6
Growth to OD600 = 0.6
at 30 jC, change to
42 jC for 15 min,
after addition of
rifampicin back to
30 jC for 1 h
No purification Band detected in
autoradiography
Reconstitution
and transport
assay
Expression only for
[35S]-labeling [109]
MIT (2.A.45)
CorA
Escherichia coli
E. coli LMG 194,
pBAD
Growth to OD600 = 0.6
at 37 jC, induction
with 0.1%
arabinose, change
to 15 jC, harvest
at OD600 = 2.5
Ni2 +–NTA
affinity column
11% of total
membrane protein,
10 mg purified
per liter culture
n.d.d Lower temperature
reduced inclusion
bodies and increased
protein insertion
into membrane
a Unless indicated otherwise, growth medium was Luria Broth (LB), reported protein purity was at minimum 95%, and His-tag contained six tandem
histidines.
b The system of transporter families by Paulsen et al. [1,2] and Saier [5] was used for the classification of the transporter proteins.
c Not available.
d Not determined.
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system has a relatively strong promoter, overexpression of
membrane proteins with the system sometimes causes
bacterial cell death [47].
The pTTQ18 vector and its variants were used by Ward
et al. [28,36,37] to overexpress a number of prokaryotic
membrane transporters for sugars and sugar derivatives in E.
coli (Table 2). Almost 100% of the 16 transporters studied
were expressed at levels of 20–50% of total membrane
protein and purification yields of 1–2 mg per liter of culture
were obtained. Protein expression in this system is under the
control of the tac promoter. Interestingly, several of these
transporter proteins that were expressed using the tac
promoter did not express with a T7 promoter [36]. The
pTTQ18 vector, however, is not a tightly controlled system,
and IPTG-independent expression occurs in the stationary
phase [28].
Most of the currently available expression vectors,
including those mentioned above, are constructed with
affinity purification tags. The 5V end of the coding region
is believed to be important for effective initiation of trans-
lation, and thus, for expression [25]. The position of the
purification tags is therefore critical. The target gene can be
cloned into a vector in two different constructs that have the
tags at either end of the protein. If neither N- nor C-terminal
tagging leads to reasonable expression, the first 10 amino
acids of the target protein may be replaced with those from
either a homologue or an anthologue for that high expres-
sion is already established.
2.3. Host strain
Because expression levels can vary as much as 2- to 5-
fold between strains [42], several host strains should be
tested during initial trials. Several E. coli strains are com-
patible with the pET and pQE vectors, including those
deficient in proteases or with extra codons. By switching
from E. coli BL21(DE3) strain to C43(DE3), a strain
originally selected for it high capacity of producing mito-
chrondrial membrane proteins [47], Ka¨stner et al.[43] were
able to increase the protein yield for the Na+-dependent
citrate carrier of Klebsiella pneumoniae from 1 to 6.5 mg
per liter of bacterial culture (Table 2). Another strain worth
considering is the methionine auxotroph B834. It allows
efficient labeling of the target protein with selenomethio-
nine—a feature that facilitates structure determination by the
multiwavelength anomalous diffraction method.
The pBAD vector requires the host cell to be deficient in
arabinose metabolism. The E. coli LGM194 strain has the
compatible phenotypes, but is highly susceptible to bacter-
iophage infection, particularly to the T1 phage, the most
common type of bacteriophages found in a research labo-
ratory. Alternatively, BL21–pLysS may be used as the host
strain with the pBAD vector. This strain is more resistant to
T1 phage infection but is not deficient in arabinose metab-
olism. If the time for post-induction cell growth does not
exceed 2–3 h, the expression is not affected, because the
arabinose levels only decrease significantly after 6 h. Ano-
ther advantage of the BL21–pLysS strain is that, when used
with the T7 vector system, it produces lysozyme that
inhibits leaky transcription during cell culture and facilitates
cell breakage at later membrane preparation stages.
When expressing proteins from thermophilic bacteria in
E. coli, host strains that carry plasmids encoding tRNAs that
recognize rare codons should be considered, because ther-
mophilic archaebacteria use rare codons for translation [48].
Knol et al. [30] found that LacS, the lactose transporter from
Streptococcus thermophilus, expressed at lower levels in E.
coli than in S. thermophilus (Table 2). Introducing addi-
tional tRNAs for rare codons into E. coli can increase the
expression levels of archaea proteins [49]. Codon usage
between Thermoplasma acidophilum and E. coli, for exam-
ple, differs in one major aspect: the former uses the two
arginine-coding codons, AGG and AGA, whereas E. coli
uses them less frequently. These same codons are also
frequently used by eukaryotic organisms [50]. The Codon-
Plus E. coli strain from Stratagene carries plasmids coding
for these two tRNA codons, and may be useful for express-
ing T. acidophilum proteins. The BL21–Codon-Plus–RIL
strain overexpresses tRNAs for leucine and isoleucine, and
may be suitable for expressing proteins with multiple trans-
membrane fragments rich in these two amino acids.
2.4. Colony selection
Colonies need to be selected for large-scale expression
experiments, because expression levels can vary substan-
tially among colonies of transformed cells. Based on a
colony blot protocol from Qiagen [51], we have developed
a simple and systematic approach for colony selection.
Colonies on a master plate containing freshly transformed
cells are transferred to a nitrocellulose membrane. The
colonies bound to the nitrocellulose are then placed on an
LB plate containing the inducer. The cells are lysed on the
nitrocellulose after a few hours of growth, followed by
protein denaturation and binding to the membrane. The
protein of interest is then probed with the appropriate
antibody or conjugate, for example, Ni2 +–horseradish per-
oxidase (HRP) probe, on the nitrocellulose membrane (Fig.
1). High-expressing colonies are then selected from the
original plate for large-scale expression. At expression
levels above 0.1 mg/l, the signal from the target protein is
far stronger than the background signal caused by the
binding of the Ni2 +–HRP probe to histidine-rich endoge-
nous E. coli proteins. Therefore, the selection of the high-
expression colonies is not affected by the weak false-
positive signal and the method is simple and reliable.
2.5. Cell culture
Besides the vector, cell culture conditions are the most
important factors affecting expression of membrane pro-
teins. Expression levels depend on the culture medium, cell
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density at induction and harvesting, inducer concentration
and the temperature profile, particularly, the post-induction
time and temperature. Optimization of cell culture and
induction conditions can increase the expression level 3-
to 5-fold [41,42]. A cell growth curve can be used to guide
the optimization process. Induction is often carried out at the
mid log phase of cell growth, and cells are harvested before
they reach the stationary phase. A rich medium typically
leads to higher cell density and more protein expressed. On
the other hand, prolonged post-induction cell growth can
result in proteolytic degradation. For inducible promoters, it
is often beneficial to screen a wide concentration range to
find the optimal inducer concentration. Ultimately, the
protein should be expressed at a level that allows its
detection by Coomassie blue-stained sodium dodecyl sulfate
(SDS)–polyacrylamide gel electrophoresis (PAGE) of
membrane samples [41,42]. If the initial expression level
is below 0.1 mg/l cell culture, one should consider switching
to another vector, which may result in higher expression
levels.
Optimizing cell culture conditions can also reduce inclu-
sion body formation—which often occurs when the pro-
moter is strong and the machinery for membrane protein
translation and insertion becomes oversaturated [25].
Although it is possible to solubilize the inclusion bodies
with high concentrations of urea or stronger chaotropic
reagents and subsequently refold the membrane protein in
vitro, the final yield of refolded membrane protein is often
very low [52]. It is therefore best to avoid the formation of
inclusion bodies in the first place, by optimizing cell culture
conditions.
Inclusion body formation depends on the rate of protein
synthesis and the rate of protein folding [53]. By decreasing
the cell growth temperature, the formation of inclusion
bodies for a number of soluble proteins expressed in
bacteria was reduced [54]. This approach was recently
applied to expression studies of the magnesium transporter
CorA in the pBAD/LMG194 system (Chen and Wang,
unpublished results). Sixty milligrams of CorA protein per
liter of E. coli culture was produced at 37 jC. However,
most of the protein was trapped in inclusion bodies, with
only 3 mg found in the membrane fraction (Fig. 2).
Reducing the post-induction temperature to 15 jC essen-
tially eliminated inclusion body formation. Approximately
15 mg CorA/l cell culture was found in the membrane
fraction, and of this, 10 mg was purified using Ni2 +–NTA
affinity chromatography.
Unless one is certain there is no inclusion body formation
in the expression system, a low-speed centrifugation step
following cell breakage is necessary [55]. Small amounts of
unfolded membrane protein can act as seeds for aggregation
Fig. 1. Analysis of homologous expression level of the glycerol-3-
phosphate (G3P) transporter (GlpT) in E. coli. A Ni2 +–HRP Western blot
of a colony-blot preparation revealed various GlpT expression levels.
Colonies with the highest signals gave a purification yield of 1.5 mg/l
culture. Note that all colonies transferred to the nitrocellulose membrane
were of similar size.
Fig. 2. Effect of post-induction cell growth temperature to homologous
expression of magnesium transporter (CorA) from E. coli. E. coli LMG194
cells carrying the CorA gene in the pBAD vector were grown at 37 jC to
OD600f 0.6, followed by induction of gene expression with 0.01%
arabinose. Cells cultured at different post-induction temperatures were all
grown to OD600f 2.5. Following cell breakage and fractionation, samples
were analyzed by Coomassie blue-stained SDS-PAGE. (A) Total cell lysate.
(B) Solubilized membrane. The total amount of CorA protein produced,
about 60 mg/l E. coli culture, decreased only slightly at lower post-induction
temperature. Lowering the post-induction temperature, however, resulted in
significantly more CorA insertion into the membrane (f 15 mg/l culture).
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and, therefore, hinders crystallization. A low-speed centri-
fugation step prevents contamination by inclusion bodies in
subsequent membrane preparations, and thus minimizes co-
purification of unfolded polypeptide along with the properly
folded protein [42].
3. Factors important for protein quality
Protein quality is as important as quantity for structural
studies, and a system with the highest expression levels may
not produce the best quality protein for crystallization
[42,56]. Therefore, once an expression system is established
that produces reasonable amounts of the membrane trans-
porter protein, the protein construct, cell culture conditions,
and purification proteins should all be optimized. At this
point, the protein’s stability and functionality should be also
analyzed to prepare for crystallization experiments.
3.1. Protein construct
The most important parameter in protein crystallization is
the protein itself [57]. Flexible termini and loops in a protein
often hinder the formation of high-quality crystals. After the
removal of such flexible termini, the protein core tends to
crystallize more readily. As a result, it is now a standard
procedure for improving crystal quality by identifying the
protein core and redesigning the protein construct accord-
ingly [22,57,58].
Mass spectrometry, in combination with limited proteol-
ysis, provides a useful tool for identifying polypeptides.
Previously, the technique’s application in the analysis of
membrane proteins was limited [59]; the presence of deter-
gent and lipid in the membrane protein sample precluded
accurate molecular mass measurements [28]. Recently,
Cadene and Chait [60] introduced a wash step with tri-
fluoroacetic acid that removes lipid and detergent from the
protein. This method allowed them to determine molecular
mass of 20–50 kDa membrane proteins with an accuracy of
F 2–4 Da using matrix-assisted laser desorption/ionization
time-of-flight (MALDI-TOF) mass spectrometry, and thus,
to identify membrane proteins unequivocally. The rigid core
of both the GlpT (Fig. 3) and GabP proteins was identified
using this procedure, and their plasmids redesigned and
recloned accordingly [41,42]. The resulting GlpT protein
core was resistant to proteases and retained full activity
[42,61]. One limitation of this entire procedure, however, is
that it cannot easily identify and eliminate flexible loops in
the middle of the protein sequence.
At the protein level, one can increase its solvent-acces-
sible surface areas available for making crystal contacts by
conformation-specific antibody binding [62] or by fusing a
soluble protein into the membrane protein sequence as a
‘carrier’ for crystallization. Cytochrome b562, an easily
crystallizable copper-binding protein, and other soluble
proteins of various sizes were inserted into loops of the
Lac permease (LacY) from E. coli [63,64]. Several of the
fusion proteins retained their ability to transport lactose.
However, it is still unknown if these fused proteins will
yield crystals more readily. A potential problem is the issue
of flexibility between the target and ‘carrier’ protein which
may hinder high-quality crystal formation.
3.2. Cell culture
The importance of cell culture conditions on protein
quality and the potentials for their optimization are illus-
trated by the studies on GlpT [42]: initially, GlpT protein
expression level was 8 mg/l culture, which yielded 4 mg
purified protein. However, protein microheterogeneity, pre-
sumably due to proteolytic digestion and post-translational
modification, was detected by SDS-PAGE of purified
samples (Fig. 4). In addition, two proteins co-purified with
Fig. 3. Identification of flexible termini and optimization of GlpT
constructs. (A) Initially, the wild-type GlpT was expressed in the pBAD
vector, with a myc-epitope and a His6-tag fused to its C terminus. In
addition to the Leu2!Gly2 mutation introduced to facilitate cloning, the
N-terminal methionine (Met1) was found to be proteolytically removed in
vivo. The molecular weight of the expressed protein, therefore, was
calculated to be 53,013. This was confirmed by MALDI-TOF mass
spectroscopy measurements, which yielded a value of 53,017. (B) Ni2 +–
NTA purified wild-type GlpT protein was subjected to tryptic digestion at
different enzyme-to-protein ratios for various periods of time. Three
digestion products ending with residue Arg449, Lys453 and Lys459,
respectively, were identified by SDS-PAGE followed by mass spectroscopy.
(B) A new DNA construct was then engineered, containing residues 1–448,
the protein core, followed by a thrombin-specific proteolytic and the myc-
His-tags.
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GlpT on Ni2 +–NTA affinity column that could not be
separated from the transporter by an additional chromatog-
raphy step. Purification with a third chromatography col-
umn results in protein aggregation due to delipidation, as
often occurs with polytopic membrane proteins [65,66].
However, multiple cycles of cell culture condition optimi-
zation, including inducer concentration and the time and
temperature for cell growth, solved most of these problems
and resulted in 1.8 mg of purified GlpT per liter of E. coli
culture [42].
3.3. Protein homogeneity
A protein is more likely to crystallize if it is in a
homogeneous state [57]. Heterogeneities are either confor-
mational or biochemical in nature. Conformational hetero-
geneity is related to protein flexibility and multiple con-
formations required for the protein’s function. Besides
protein impurity and variations in polypeptide sequence,
biochemical heterogeneity is also related to detergent and
co-purified lipid. While the protein purity and microhete-
rogeneity can be readily detected using SDS-PAGE and
mass spectrometry [42,61], the detergent and co-purified
lipid should also be monitored for crystallization experi-
ments.
Conformational heterogeneity due to intrinsic structural
flexibility of membrane transporter proteins may interfere
with the crystallization process. In contrast to proteins
whose reaction cycle involves only the prosthetic groups
bound [67,68], transporter proteins are highly flexible. This
is particularly true for transporters that translocate large
solute molecules across the membrane. Studies on the Lac
permease, a prototype for 12 a-helices membrane trans-
porters, illustrate the intrinsic structural flexibility of mem-
brane transporters [69]. Upon substrate binding, the distance
between helices II and VII of the protein changed by more
than 4 A˚. The average tilt angle of helices from the
membrane normal, measured by Fourier transform infrared
spectroscopy, changed from 33j to 51j with a decreased
lipid-to-protein ratio [70]. The long loop connecting helices
6 and 7 in GlpT also displayed conformational changes
upon substrate binding [61]. Conformational heterogeneity
due to structural flexibility can be reduced by substrate and
inhibitor binding. Using circular dichroism spectroscopy of
purified protein, Fu and Maloney [71] observed markedly
increased structural stability of the E. coli oxalate trans-
porter (OxlT) in the presence of substrate in a detergent/lipid
micellar environment. Similarly, the binding of GlpT to its
substrate, G3P, locked the transporter into a particular
conformation, protecting the long central loop of the protein
from tryptic digestion [61].
Another source of biochemical heterogeneity comes from
free, unbound detergent in solution, which may prevent
proper packing of protein–detergent micelles in the crystal
lattice. Detergent concentration, therefore, needs to be kept
at a minimum that maintains protein solubility. For low
critical micellar concentration (CMC) detergents like dode-
cylmaltoside (DDM) or octyloxyethylene dodecylether
(C12E8), a final concentration of 0.1–0.2% appears to be
appropriate for a protein concentration of 5–10 mg/ml
during crystallization. This detergent concentration can be
achieved by careful control of the detergent concentration
used in the last purification column, followed by a concen-
tration step using filters with an appropriate molecular
weight cut-off.
Lipids typically co-purify with membrane proteins, lead-
ing to additional biochemical heterogeneity. On the other
hand, complete delipidation of membrane transporter pro-
teins often causes denaturation and aggregation [42,65,66].
It is therefore necessary to identify the lipids that are
critical for the protein’s stability and subsequently to
control their composition in the purified sample [65].
Following extraction using organic solvent, phospholipids
co-purifying with the protein can be identified by two-
dimensional thin-layer chromatography, and their concen-
trations measured by phosphate analysis [65,66,72]. Anal-
ysis of protein samples purified with two successive
Fig. 4. Optimization of the E. coli cell culture for GlpT overexpression. The
protein core of GlpT expressed in pBAD vector migrated on SDS-PAGE to
a position corresponding to a molecular weight of 45,000, as indicated by
letter ‘b’. Lane 1: When the E. coli cells were cultured at 37 jC to OD600 of
1.0 and then induced with 0.2% arabinose, growth at 37 jC for an
additional 2 h to OD600 of 2.3 produced a number of contamination protein
bands that could not be isolated from GlpT by Ni2 +–NTA or size-exclusion
column. Two unidentified proteins at 58 and 32 kDa, labeled by letters ‘a’
and ‘d’, co-purified with GlpT on the Ni2 +–NTA resin and could not be
separated from the transporter protein by a subsequent size-exclusion or
ion-exchange column. The protein bands indicated by letter ‘c’ consisted of
several proteolyzed GlpT fragments and a broad ‘shadow band,’ appearing
2–3 kDa below the GlpT protein. Lane 2: Reducing the arabinose
concentration for induction from 0.2% to 0.1% and lowering the
temperature after induction to 25 jC minimized the expression of the 58-
and 32-kDa proteins. Changing the induction OD600 from 1.0 to 0.5 and
shortening the post-induction period from 2 to 1.5 h markedly reduced the
proteolysis fragments. Lane 3: Following thrombin digestion, both GlpT
and the shadow band shifted downwards by the same distance, suggesting
that the shadow band was either a post-translational modification or an N-
terminal truncation of GlpT. Lane 4: Lowering the temperature from 37 to
25 jC half hour before induction resulted in essentially the complete
disappearance of the shadow band. The OD600 at cell harvest was 1.5. All
protein samples were purified by Ni2 +–NTA affinity chromatography
before SDS-PAGE analysis (reproduced from Ref. [42] with permission).
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chromatography columns showed that five to eight phos-
pholipid molecules typically co-purify with one transporter
molecule of 12–14 transmembrane a-helices [65,66,72].
Lipid type and concentration were critical for two- and
three-dimensional crystal formation of several membrane
proteins [66,73].
3.4. Protein stability and monodispersity
Crystallization requires a protein to be stable and mono-
disperse at 4 or 20 jC over several days or weeks [74–76].
Due to their surface duality, being both hydrophilic and
hydrophobic, membrane proteins tend to aggregate and
precipitate quickly in the presence of unfavorable deter-
gents, precluding crystallization. This is a challenge espe-
cially for transporter proteins because of their high number
of multiple transmembrane spans and larger areas of hydro-
phobic surface [65].
While each individual protein demonstrates unique sen-
sitivities to its environment, detergent, lipid, pH, and tem-
perature have been shown to affect the stability and
monodispersity of many transporter proteins. In addition,
glycerol at concentrations of 20% is highly effective in
increasing the stability of membrane transporters [27,41,42,
65,77], in agreement with its stabilizing effect for soluble
proteins [78]. Using analytical size-exclusion chromatogra-
phy on high-performance liquid chromatography (HPLC)
[79], a large number of conditions can be screened effi-
ciently. Those conditions that keep the protein stable and
monodisperse can be applied to both purification and
crystallization.
Using the above procedure, the GlpT protein was found
to be monomeric between pH 4.5 and 8.5, and in 9 of the 15
detergents tested (Fig. 5) [42]. In contrast, the GlpT
homologue from Haemophilus influenzae, with a 56%
sequence identity to the E. coli protein, was not stable in
DDM (Lemieux, Song and Wang, unpublished data), a mild
detergent routinely used for solubilization and purification
of membrane transporters [27,28,41,42,66]. The E. coli
GABA transporter stayed monodisperse in two detergents,
DDM and Fos-Choline-12 [41]. The glutamate transporter
(GltT) from Bacillus stearothermophilus, in contrast,
proved to be an extremely stable membrane protein. It
remained dimeric from pH 4 to 9 in a number of detergents,
including DDM, undecylmaltoside (UDM), decylmaltoside
(DM), nonylmaltoside (NM), cyclohexyl-hexylmaltoside
(Cymal-6), cyclohexyl-pentylmaltoside (Cymal-5), Fos-
Choline-12, Fos-Choline-10, MEGA-10, OG and lauryldi-
methylamine oxide (LDAO) (Lemieux, Slotboom, Lolkema
and Wang, unpublished results). Furthermore, after incuba-
tion at 37 jC for 2 h, no aggregation or change in
oligomeric state was detected. Such unusual stability is
probably related to the fact that the protein is from a
thermophilic bacterium. It remains to be seen whether other
transporter proteins from thermophilic organisms are e-
qually stable.
3.5. Protein activity
Activity and integrity of the expressed transporter should
be monitored to ensure that the structure determined is of
physiological relevance. Functionality can be studied in
membrane and detergent solution, each revealing properties
of the protein in different environments. Measuring trans-
porter activity in whole bacterial cells provides a direct and
relatively quick activity assay. Activity for a particular
substrate is measured before and after induction of protein
expression, and the difference in transport activity is corre-
lated to the functionality of the expressed protein [31,63,80,
81]. This approach, however, often does not yield reliable
transport kinetics of the expressed protein. This is due most
likely to: low-level leaky expression, the difficulties in
estimating the number of transporter molecules expressed
per cell, or possible multiple transport systems for a partic-
ular substrate. E. coli, for example, has four transport
systems for inorganic phosphate (Pi) [17]. In addition, at
high expression levels, the total substrate flux in cells can be
so high, that the transport assay becomes oversaturated. The
main advantage of the whole-cell measurement techniques
therefore lies in rapid evaluation of the correct folding and
functionality of the transporter in expression experiments.
More reliable measurement of the transport kinetics
requires reconstitution of the purified protein into proteoli-
posomes, followed by transport activity assays [28]. These
experiments have been conducted for many transporters
Fig. 5. Monodispersity of the GlpT protein in the presence of different
detergents. The control was kept at 4 jC. All other samples were incubated
with different detergents for 2 h at 25 jC, followed by analytical size-
exclusion chromatography on HPLC. Eluted as single peak, the protein
remained monomeric and monodisperse in a number of detergents:
decylglucoside (DG), decylmaltoside (DM), undecylmaltoside (UDM),
dodecylmaltoside (DDM), Cymal-5, Cymal-6, Triton X-100, C12E8 and
HEGA-10 (reproduced from Ref. [42] with permission).
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(Table 2). Typically, reconstitution of the transporter is
achieved by mixing preformed lipid vesicles and purified
protein in the presence of detergent, followed by detergent
removal with Bio-Beads [82]. Substrate transport across the
membrane of the proteoliposomes is measured using an
enzymatic or radioactivity assay. These measurements yield
the Vmax, Kd, turnover rate, and other parameters of the
transport kinetics [30,42,83].
The activity of the transporter in whole cell or proteoli-
posomes only reflects its properties in a lipid environment—
but it is the functionality of the transporter in detergent
solution that is particularly useful to protein crystallization.
Direct measurement of the transport activity of membrane
transporters in solution is impossible because of the vecto-
rial nature of the transport process and the isotropy of the
solubilized protein. Nonetheless, substrate binding to the
solubilized protein can be studied in detergent solution,
using various biophysical and spectroscopic techniques.
Fluorescence quenching upon substrate binding was used
to study GalP, GlpT, and GabP proteins (Table 2)
[41,42,84], and the results indicate that the proteins retain
their substrate-binding capability in detergent solution.
Caution, however, may be necessary when drawing con-
clusions from the binding constants obtained from these
experiments. Transporter proteins, even those with a single
substrate-binding site, can adopt at least two conformations,
with the binding site facing either side of the membrane
[85]. In solution, the protein sample consists of a population
of mixed conformations, and therefore the substrate can
bind from either side, typically with different affinities.
Measurements in solution cannot easily separate the two,
unless the substrate binds to one conformation with a far
greater affinity than it does to the other. This problem can be
overcome by using whole-cell measurements, or using
inside-out and right-side-out vesicles [86,87]. While a
complete picture of a transporter’s activity can only be
derived from a combination of different functional assays,
the protein functionality should be demonstrated with at
least one experimental technique before crystallization.
4. Summary and outlook
The emphasis of membrane transporter overexpression
for structural studies should be as much on the quality of the
protein as on its quantity. Optimization, therefore, is
required at several stages of expression and purification.
The following steps are particularly important: identification
and construction of a rigid protein core, optimization of cell
culture conditions to improve protein quantity and quality,
and screening for conditions that maintain protein stability
and monodispersity. In addition, the issues raised in this
review will probably apply to other types of prokaryotic
membrane proteins.
Many of the factors discussed here may also help in-
vestigators to overcome difficulties with overexpressing
transporter proteins from mammalian sources. To date,
efforts to overexpress mammalian membrane proteins in
bacterial systems have brought little success. One major
reason is that we do not fully understand several key steps in
the transcription, translation and membrane insertion pro-
cesses for the E. coli system. For example, we know that the
messenger RNA sequence and stability are critical for
protein expression [88,89], but we cannot predict where
secondary RNA structures are likely to form that may cause
translation termination. Nor can we predict which sequences
are particularly susceptible to degradation by nucleases.
Although we know that the formation of inclusion bodies
is a result of oversaturation of the cell’s translation and
membrane insertion machinery, we do not yet know which
steps are responsible. It is not clear if the problem is related
to solubility in the cytosol, membrane targeting, protein
insertion into the membrane, or all combined. Can one co-
express the membrane protein with chaperones to increase
the protein expression levels? If so, which chaperones
should one choose? Finally, the total amount of membrane
in a bacterial cell is limited. What is the upper limit for
expression levels of fully folded membrane proteins? Once
these basic cellular processes are better understood, we
should be able to overexpress almost any bacterial mem-
brane protein, perhaps at higher levels, and most impor-
tantly, we may achieve the ultimate goal of producing
mammalian membrane proteins in E. coli for structural
studies.
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